NO-induced migraine attack: Strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release

Pain

Volumn 106, Issue 3, 2003, Pages 461-470

  Juhasz, Gabriella ^a   Zsombok, Terezia ^a   Modos, Edit A ^a   Olajos, Sarolta ^a   Jakab, Balazs ^b   Nemeth, Jozsef ^b   Szolcsanyi, Janos ^b   Vitrai, Jozsef ^c   Bagdy, Gyorgy ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

Author keywords

Calcitonin gene related peptide; Headache; Migraine; Nitric oxide; Nitroglycerin; Platelet serotonin

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; GLYCERYL TRINITRATE; NITRIC OXIDE; SEROTONIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HEADACHE; HUMAN; MIGRAINE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SEROTONIN RELEASE; THROMBOCYTE;

EID: 0344737766     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2003.09.008     Document Type: Article

References (56)

1. Akerman S., Williamson D.J., Kaube H., Goadsby P.J. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilatation of dural meningeal vessels. Br J Pharmacol. 137:2002;62-68.
2. Diagnostic and statistical manual - IV. 1994;American Psychiatric Press, Washington, DC.
3. Anthony M. The biochemistry of migraine. Clifford Rose F. Handbook of clinical neurology. Headache. vol. 4:1986;85-104 Elsevier, Amsterdam.
4. Ashina M., Bendtsen L., Jensen R., Schifter S., Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 86:2000;133-138.
5. Ashina M., Bendtsen L., Jensen R., Schifter S., Olesen J. Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache. Eur J Neurol. 8:2001;173-178.
6. Buzzi M.G., Moskowitz M.A. The trigemino-vascular system and migraine. Pathol Biol (Paris). 40:1992;313-317.
7. Castellano A.E., Micieli G., Bellantonio P., Buzzi M.G., Marcheselli S., Pompeo F., Rossi F., Nappi G. Indomethacin increases the effect of isosorbide dinitrate on cerebral hemodynamic in migraine patients: pathogenetic and therapeutic implications. Cephalalgia. 18:1998;622-630.
8. Christiansen I., Iversen H.K., Olesen J. Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. Cephalalgia. 20:2000;437-444.
9. Dalsgaard-Nielsen T., Bryndum B., Fog-Moeller F., Genefke I.K. The effect of percutaneous nitroglycerin upon the concentration of serotonin, epinephrine and norepinephrine in venous blood from migrainous subjects during attack-free intervals. Headache. 14:1975;231-234.
10. D'Amico D., Ferraris A., Leone M., Catania A., Carlin A., Grazzi L., Bussone G. Increased plasma nitrites in migraine and cluster headache patients in interictal period: basal hyperactivity of L-arginine-NO pathway? Cephalalgia. 22:2002;33-36.
11. Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin Investig Drugs. 2:2001;1261-1268.
12. Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., Eberlein W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 129:2000;420-423.
13. Durham P.L., Russo A.F. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drugs. J Neurosci. 19:1999;3423-3429.
14. Edvinsson L. A pathophysiological view of primary headaches. Funct Neurol. 15:(Suppl 3):2000;50-60.
15. Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs. 15:2001;745-753.
16. Eltrop C.T., Jansen-Olesen I., Hansen A.J. Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide. Cephalalgia. 20:2000;838-844.
17. Fanciulacci M., Alessandri M., Figini M., Gepetti P., Michelacci S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 60:1995;119-123.
18. Ferrari M.D., Odink J., Tapparelli C., Van Kempen G.M., Pennings E.J., Bruyn G.W. Serotonin metabolism in migraine. Neurology. 39:1989;1239-1242.
19. Gallai V., Sarchielli P., Floridi A., Franceschini M., Codini M., Glioti G., Trequattrini A., Palumbo R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 15:1995;384-390.
20. Garry M.G., Walton L.P., Davis M.A. Capsaicin-evoked release of immunoreactive calcitonin gene-related peptide from the spinal cord is mediated by nitric oxide but not by cyclic GMP. Brain Res. 861:2000;208-219.
21. Goadsby P.J. How do the currently used prophylactic agents work in migraine? Cephalalgia. 17:1997;85-92.
22. Goadsby P.J., Edvinsson L. The trigemino-vascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 33:1993;48-56.
23. Goadsby P.J., Edvinsson L. Neuropeptide changes in a case of chronic paroxysmal hemicrania - evidence for trigemino-parasympathetic activation. Cephalalgia. 16:1996;448-450.
24. 1B/1D receptor: a central action in migraine? Ann Neurol. 43:1998;711-718.
25. Goadsby P.J., Edvinsson L., Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 28:1990;183-187.
26. Griffiths L.R., Nyholt D.R., Curtain R.P., Goadsby P.J., Brimage P.J. Migraine association and linkage studies of endothelial nitric oxide synthase (NOS3) gene polymorphism. Neurology. 49:1997;614-617.
27. Guicheney P. Human platelet serotonin content: methodological aspects and physiological variations. Meth Find Exptl Clin Pharmacol. 10:1988;253-258.
28. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 8:(Suppl 7):1988;1-96.
29. Iversen H.K. Experimental headache in humans. Cephalalgia. 15:1995;281-287.
30. Iversen H.K., Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 16:1996;412-418.
31. Johnson K.W., Phebus L.A., Cohen M.L. Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res. 51:1998;219-244.
32. Juhasz G., Zsombok T., Laszik A., Jakus R., Faludi G., Sotonyi P., Bagdy G. Despite the general correlation of the serotonin transporter gene regulatory region polymorphism (5-HTTLPR) and platelet serotonin (5-HT) concentration, lower platelet serotonin concentration in migraine patients is independent of the 5-HTTLPR variants. Neurosci Lett. 350:2003;56-60.
33. Kantor S., Graf M., Anhauer Z.E., Bagdy G. Rapid desensitization of 5-HT1A receptors in Fawn-Hooded rats after chronic fluoxetine treatment. Eur Neuropharmacol. 11:2001;15-24.
34. Knyihar-Csillik E., Vecsei L. Effect of nitric oxide donor on nitroxergic nerve fibres in the rat dura mater. Neurosci Lett. 260:1999;97-100.
35. Knyihar-Csillik E., Tajti J., Samsam M., Sáry G., Slezak S., Vecsei L. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J Neurosci Res. 48:1997;449-464.
36. Knyihar-Csillik E., Tajti J., Chadaide Z., Csillik B., Vecsei L. Functional immunochemistry of neuropeptides and nitric oxide synthase in the nerve fibres of the supratentorial dura mater in an experimental migraine. Microsc Res Tech. 53:2001;193-211.
37. Lassen L.H., Haderslev P.A., Jacobsen V.B., Iversen H.K., Sperling B., Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 22:2002;54-61.
38. Nakano T., Shimomura T., Takahashi K., Ikawa S. Platelet substance P and 5-hydroxytryptamine in migraine and tension-type headache. Headache. 33:1993;528-532.
39. Nemeth J., Gorcs T., Helyes Z., Oroszi G., Kocsy T., Pinter E., Szolcsanyi J. Development of a new sensitive CGRP radioimmunoassay for neuropharmacological research. Neurobiology. 6:1998;473-475.
40. 125I-labeling and purification of peptide hormones and bovine serum albumin. J Radioanal Nucl Chem. 251:2002;129-133.
41. Ohkuma S., Katsura M. Nitric oxide and peroxynitrite as factors to stimulate neurotransmitter release in the CNS. Prog Neurobiol. 64:2001;97-108.
42. Olesen J., Iversen H.K., Thomsen L.L. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. NeuroReport. 4:1993;1027-1030.
43. Olesen J., Thomsen L.L., Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci. 15:1994;149-153.
44. Pardutz A., Krizbai I., Multon S., Vecsei L., Schoenen J. Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. NeuroReport. 11:2000;3071-3075.
45. Pardutz A., Multon S., Malgrange B., Parducz A., Vecsei L., Schoenen J. Effect of systemic nitroglycerin on CGRP and 5-HT afferents to rat caudal spinal trigeminal nucleus and its modulation by estrogen. Eur J Neurosci. 15:2002;1803-1809.
46. Prast H., Philippu A. Nitric oxide as modulator of neuronal function. Prog Neurobiol. 64:2001;51-68.
47. Reuter U., Bolay H., Jansen-Olesen I., Chiarugi A., Sanchez del Rio M., Letourneau R., Theoharides T.C., Waeber C., Moskowitz M.A. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain. 124:2001;2490-2502.
48. Sarchielli P., Gallai V. Platelets in migraine. J Headache Pain. 2:2001;S61-S66.
49. Sarchielli P., Alberti A., Codini M., Floridi A., Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia. 20:2000;907-918.
50. Sarchielli P., Alberti A., Floridi A., Gallai V. L-Arginine/nitric oxide pathway in chronic tension-type headache: relation with serotonin content and secretion and glutamate content. J Neurol Sci. 198:2002;9-15.
51. Srikiatkhachorn A., Anuntasethakul T., Phansuwan-Pujito P., Patumraj S., Kasantikul V. Effect of serotonin depletion on nitric oxide induced cerebrovascular nociceptive response. NeuroReport. 12:2001;967-971.
52. Tagliaferro P., Ramos A.J., López-Costa J.J., López E.M., Saavedra J.P., Brusco A. Increased nitric oxide synthase activity in a model of serotonin depletion. Brain Res Bull. 54:2001;199-205.
53. Tassorelli C., Joseph A.S. Systemic nitroglycerin activates peptidergic and catecholaminergic pathways in rat brain. Peptides. 17:1996;443-449.
54. Tassorelli C., Blandini F., Costa A., Preza E., Nappi G. Nitroglycerin-induced activation of monoaminergic transmission in the rat. Cephalalgia. 22:2002;226-232.
55. Waldenlind E., Ross S.B., Saaf J., Ekbom K., Wetterberg L. Concentration and uptake of 5-hydroxytryptamine in platelets from cluster headache and migraine patents. Cephalalgia. 5:1985;45-54.
56. Zicari A., Giacovazzo M., Martelletti P. Nitric oxide: emerging implications for headache mechanics. J Headache Pain. 2:2001;67-72.